Abstract
Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Current Neuropharmacology
Title: Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Volume: 8 Issue: 3
Author(s): Dirk Fitzner and Mikael Simons
Affiliation:
Keywords: Multiple sclerosis, chronic progression, inflammation, neurodegeneration, treatment
Abstract: Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last decade, the therapeutic options for chronic progressive MS, both primary and secondary, are still limited. In order to find new pharmacological targets for the treatment of chronic progressive MS, the mechanisms of the underlying neurodegenerative process that becomes apparent as the disease progresses need to be elucidated. New animal models with prominent and widespread progressive degenerative components of MS have to be established to study both inflammatory and non-inflammatory mechanisms of neurodegeneration. Here, we discuss disease mechanisms and treatment strategies for chronic progressive MS.
Export Options
About this article
Cite this article as:
Fitzner Dirk and Simons Mikael, Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246218
DOI https://dx.doi.org/10.2174/157015910792246218 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews RNAi for the Treatment of Prion Disease: A Window for Intervention in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Identification of HIV Inhibitors Guided by Free Energy Perturbation Calculations
Current Pharmaceutical Design Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Picornavirus IRES: Structure Function Relationship
Current Pharmaceutical Design Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Dengue Virus Entry/Fusion Inhibition By Small Bioactive Molecules: A Critical Review
Mini-Reviews in Medicinal Chemistry Parkinsons Disease and Obsessive-Compulsive Phenomena: A Systematic Review
Current Psychiatry Reviews The Role of Immune System in Schizophrenia
Current Immunology Reviews (Discontinued) Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Diversity in the Accessory Proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV Betacoronaviruses
Current Protein & Peptide Science Cannabinoids and Memory; Animal Studies
Current Drug Targets - CNS & Neurological Disorders Neuro-Immune-Endocrine Mechanisms During Septic Shock: Role For Nitric Oxide in Vasopressin and Oxytocin Release
Endocrine, Metabolic & Immune Disorders - Drug Targets CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Conformational Hotspots of Dengue Virus NS5 RdRp
Current Bioinformatics Attenuated D2 16681-PDK53 Vaccine: Defining Humoral and Cell- Mediated Immunity
Current Pharmaceutical Design Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets